The revenue hit faced by Cubist Pharmaceuticals from generic competition may not be as dramatic as it has been for other drugs, Cantor Fitzgerald said Tuesday, as it raised its rating on the drugmaker. Earlier this month, it said the Food and Drug Administration has given fast-track status to an experimental antibiotic regimen as a treatment for th
After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises; the number of New Molecular Entities approved by the US FDA has leveled out and biotech companies share prices are rising, indicating profitable business models. Now is the time for launch. Arthur D. Little s latest vie
ALISO VIEJO, Calif., May 21, 2013/ PRNewswire/ Bausch+ Lomb, the global eye health company, today announced that it is has received approval from the U.S. Food and Drug Administration for the TRULIGN? Toric posterior chamber intraocular lens. Jay Pepose, M.D., Ph.D, of the Pepose Vision Institute in St. Louis, MO, and medical monitor of the FDA
Baxter International Inc. and Halozyme Therapeutics, Inc., today announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. This represents an important advance for patients who ar
BioElectronics Corp., the maker of inexpensive, disposable drug-free consumer electronic devices, announced that CEO, Andrew J. Whelan is presenting today to the FDA' s Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments for reclassifying the company's products for over the counter sales. "It's been 37 years since
Today Biogen Idec announced it has submitted a Biologics License Application to the U.S. Food and Drug Administration for approval of PLEGRIDY?, the company s pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis. In addition to the BLA filing with the FDA, Biogen Idec plans to submit a Marketing Authorisation A
Cancer Treatment Centers of America at Eastern Regional Medical Center proudly announced today that it has received the Healthgrades 2013 Outstanding Patient Experience Award?. This honor ranks CTCA at Eastern among the top five percent of hospitals identified for outstanding performance in delivering a positive experience for patients during the
Cardica, Inc. said that it has completed enrollment in the European clinical study for its MicroCutter XCHANGE 30, a cartridge- based cutting/stapling device with a 5- millimeter shaft diameter and cross-sectional area more than six times smaller than standard 12- millimeter surgical staplers used today. The trial is designed to evaluate the safety
The class will be held at Dentons Offices in Palo Alto, and streamed online. Case studies will include data exchange, archival, and electronic submission to regulatory agencies such as the FDA. Pharmaceutical companies are requiring from their new hires to understand and apply CDISC standards, to comply with the latest FDA requirements and generate
Two executives from human resources and pharmacy consulting firm Solid Benefits Guidance will identify which strategies can be most effective to better manage costly specialty therapies while ensuring high-quality care to the members who are taking them, in an upcoming May 30 webinar from Atlantic Information Services, Inc., How to Manage Specia
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced initial data from a Phase 1 b clinical trial evaluating the pharmacokinetics and safety of aldoxorubicin, its novel conjugate of the widely used chemotherapeutic agent doxorubicin, in patients with metastatic solid tumors who have either...
Global Vision, the industry leader in the development of automated proofreading solutions, today announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency for pharmaceutical companies using parallel distribution methods of medicinal products. We have worked diligently with o
Montreal, CANADA Global Vision, the industry leader in the development of automated proofreading solutions, today announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency for pharmaceutical companies using parallel distribution methods of medicinal products.
Hasbro Children's Hospital, Providence, R.I., will present how significant improvements in the way they met the meal ordering needs of their patients helped increase patient satisfaction and improve workflow efficiencies for the care team during an upcoming webinar, Creating an Engaging Meal Ordering Experience for Patients. Potato Head to make foo
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to discuss new drug application 204569, for suvorexant tablets, submitted by Merck Sharp and Dohme Corp., Worldwide Regulatory Group for insomnia characterized by difficulties with sleep ons
Healthcare Solutions, the parent company of Cypress Care, ScripNet and Procura Management, today announced that it was honored to receive the Catamaran Innovation Award at Catamaran s client advisory meeting. Since the start of our relationship in 2011, Healthcare Solutions and Catamaran have worked collaboratively to identify opportunities t
Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration approved the use of Hologic' s new C-View 2 D imaging software. C-View 2 D images may now be used i
Date: Tuesday, May 21, 2013. Selectively Targeting Genes Ribonucleic acid is an interesting macromolecule that performs multiple vital roles in the coding, decoding, regulation and expression of genes, as we discussed in our April 26th article RXi Pharmaceuticals: Realizing RNA s Revolutionary Potential. With the approval of Isis Pharmaceuticals
By a News Reporter-Staff News Editor at China Weekly News Japan's pharmaceutical industry, the world's second largest, was worth USD 89 billion in 2011, representing 10 per cent of the global market share. Meantime, the regulatory reforms and government-industry cooperation have improved the global competitiveness of Japan's pharmaceutical market
Developed in collaboration with clinical studies at the Cleveland Clinic and University of Minnesota, the system is FDA cleared to market in the United States, is CE Marked, and has Health Canada and Australian TGA approval for distribution in international markets. Deep brain stimulation represents a growing therapy for movement disorders such as.
May 21 RALEIGH The state Senate's $20.6 billion budget signals a fundamental remake of state government in which some health care providers who treat poor people will be paid based on efficiency, teacher pay will be based on merit, and low-income people receiving medical care at no or low cost will have to pay more. While the new Senate budget
Accuray Incorporated, announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy. "Stereotactic Body Radiotherapy for Localized Prostate Cancer: Disease Control and Quality of li
With this acquisition Novo expands its long-term investment portfolio with a further major life-science company in Denmark and will contribute to the future growth of Xellia.. OSLO& COPENHAGEN Xellia Pharmaceuticals, a pharmaceutical group focusing on the development, manufacturing and global commercialization of anti-infective therapies, annou
Dublin- Research and Markets has announced the addition of the "Tysabri- Forecast and Market Analysis to 2022" report to their offering. The dominance of first-line injectable DMTs, including the interferon beta agents: Bayer's Betaseron/Betaferon, Biogen's Avonex and Merck's Rebif, and Teva's Copaxone, has been a salient feature of the MS therapeu
Campaign launched during World Health Assembly, where world's health ministers gather to address the large physical and economic costs of these disorders. Today the International Federation of Pharmaceutical Manufacturers and Associations launched the' Do You Mind? The campaign launch takes place at the start of the 66th World Health Assembly, wh
